(Q39998826)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

title

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

author name string

L R Coney

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

G J Fleuren

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

S O Warnaar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

S V Litvinov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

language of work or name

English

0 references

publication date

1 September 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

19 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

page(s)

735-744

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bjc.1996.430

19 October 2019

exact match

0 references

cites work

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: Relative effects of size and affinity

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Purification of bispecific F(ab')2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Human immune response to multiple injections of murine monoclonal IgG.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Radioimmunotherapy of gastrointestinal cancer and glioblastomas.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2074712

Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen

20 August 2018

1 reference

12 December 2020

Absence of preferential homologous H/L chain association in hybrid hybridomas

1 reference

12 December 2020

Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody

1 reference

12 December 2020

Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy

1 reference

12 December 2020

Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney

1 reference

12 December 2020

Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms

1 reference

12 December 2020

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

1 reference

12 December 2020

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

12 December 2020

Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components

1 reference

12 December 2020

Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies

1 reference

12 December 2020

Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

1 reference

12 December 2020

Effects of halting a cervical screening programme

1 reference

12 December 2020

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

Going both ways: bispecific antibodies and targeted cellular cytotoxicity

1 reference

12 December 2020

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma

1 reference

12 December 2020

Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant human interleukin-2

1 reference

12 December 2020

Treatment of mice bearing BCL1 lymphoma with bispecific antibodies

1 reference

12 December 2020

Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2

1 reference

12 December 2020

Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells

1 reference

12 December 2020

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250

1 reference

12 December 2020

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2

1 reference

12 December 2020

Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3

1 reference

12 December 2020

A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer

1 reference

12 December 2020

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1996.430

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8795576%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

PubMed publication ID

8795576

1 reference